Sperm protein 17 is a novel marker for predicting cisplatin response in esophageal squamous cancer cell lines

International Journal of Cancer

Volumn 126, Issue 6, 2010, Pages 1494-1503

  Kausar, Tasneem ^a,b   Ahsan, Aarif ^c   Hasan, Md Raghibul ^a   Lin, Lin ^b   Beer, David G ^b,c   Ralhan, Ranju ^a,d,e  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d MOUNT SINAI HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cisplatin; Drug resistance; Esophageal squamous cell carcinoma; Sperm protein 17

Indexed keywords

CISPLATIN; ERLOTINIB; GELDANAMYCIN; GEMCITABINE; PROTEIN; SPERM PROTEIN 17; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARCINOGENESIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HYPOTHESIS; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THERAPY RESISTANCE; TRANSCRIPTION REGULATION; TREATMENT RESPONSE; ULTRAVIOLET SPECTROPHOTOMETRY; UPREGULATION;

ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS; BENZOQUINONES; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CARRIER PROTEINS; CELL LINE, TUMOR; CISPLATIN; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LACTAMS, MACROCYCLIC; MASS SPECTROMETRY; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; QUINAZOLINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 74949092719     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24828     Document Type: Article

References (40)

1. IARC. Globocan 2002: cancer incidence, mortality and prevalence worldwide, version 1.0, IARC cancer base no. 5. Lyon: IARC Press, 2005.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55: 74-108.
3. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349:2241-52.
4. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
5. Zacherl J, Sendler A, Stein HJ, Ott K, Feith M, Jakesz R, Siewert JR, Fink U. Current status of neoadjuvant therapy for adenocarcinoma of the distal esophagus. World J Surg 2003;27:1067-74.
6. Brücher BL, Stein HJ, Zimmermann F, Werner M, Sarbia M, Busch R, Dittler HJ, Molls M, Fink U, Siewert JR. Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial. Eur J Surg Oncol 2004;30:963-71.
7. Ancona E, Ruol A, Castoro C, Chiarion-Sileni V, Merigliano S, Santi S, Bonavina L, Peracchia A. First-line chemotherapy improves the resection rate and longterm survival of locally advanced (T4, any N, M0) squamous cell carcinoma of the thoracic esophagus: final report on 163 consecutive patients with 5-year follow-up. Ann Surg 1997;226: 714-23.
8. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, Minsky BD, Roth JA. Chemotherapy followed by surgery compared with surgery alonefor localized esophageal cancer. N Engl J Med 1998;339:1979-84.
9. Greer SE, Goodney PP, Sutton JE, Birkmeyer JD. Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. Surgery 2005; 137:172-7.
10. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J, Australasian Gastro-Intestinal Trials Group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007;8:226-34.
11. Lim SH, Wang Z, Chiriva-Internati M, Xue Y. Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma. Blood 2001; 97:1508-10.
12. Chiriva-Internati M, Wang Z, Xue Y, Bumm K, Hahn AB, Lim SH. Sperm protein 17 (Sp17) in multiple myeloma: opportunity for myeloma-specific donor T cell infusion to enhance graft-versusmyeloma effect without increasing graftversus-host disease risk. Eur J Immunol 2001;31:2277-83.
13. De Jong A, Buchli R, Robbins D. Characterization of sperm protein 17 in human somatic and neoplastic tissue. Cancer Lett 2002;186:201-9.
14. Chiriva-Internati M, Grizzi F, Weidanz JA, Ferrari R, Yuefei Y, Velez B, Shearer MH, Lowe DB, Frezza EE, Cobos E, Kast WM, Kennedy RC. A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Sp17. J Immunol Methods 2007; 321:86-93.
15. Mashino K, Sadanaga N, Tanaka F, Yamaguchi H, Nagashima H, Inoue H, Sugimachi K, Mori M. Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br J Cancer 2001;85:713-20.
16. Bumm K, Grizzi F, Franceschini B, Koch M, Iro H, Wurm J, Ceva-Grimaldi G, Dimmler A, Cobos E, Dioguardi N, Sinha UK, Kast WM, et al.Sperm protein 17 expression defines 2 subsets of primary esthesioneuroblastoma. Hum Pathol 2005; 36:1289-93.
17. Sharma R, Samantaray S, Shukla NK, Ralhan R. Transcriptional gene expression profile of human esophageal squamous cell carcinoma. Genomics 2003;81:481-8.
18. Gupta G, Sharma R, Chattopadhyay TK, Gupta SD, Ralhan R. Clinical significance of sperm protein 17 expression and immunogenicity in esophageal cancer. Int J Cancer 2007;120:1739-47.
19. Nakazato T, Kanuma T, Tamura T, Faried LS, Aoki H, Minegishi T. Sperm protein 17 influences the tissue-specific malignancy of clear cell adenocarcinoma in human epithelial ovarian cancer. Int J Gynecol Cancer 2007;17:426-32.
20. Paris R, Morales A, Coll O, Sánchez-Reyes A, García-Ruiz C, Fernández-Checa JC. Ganglioside GD3 sensitizes human hepatoma cells to cancer therapy. J Biol Chem 2002;277:49870-6.
21. Li Z, Xu M, Xing S, Ho WT, Ishii T, Li Q, Fu X, Zhao ZJ. Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem 2007;282: 3428-32.
22. Parsels LA, Morgan MA, Tanska DM, Parsels JD, Palmer BD, Booth RJ, Denny WA, Canman CE, Kraker AJ, Lawrence TS, Maybaum J. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol Cancer Ther 2009;8:45-54.
23. Sreedhar AS, Mihály K, Pató B, Schnaider T, Steták A, Kis-Petik K, Fidy J, Simonics T, Maraz A, Csermely P. Hsp90 inhibition accelerates cell lysis. Anti-Hsp90 ribozyme reveals a complex mechanism of Hsp90 inhibitors involving both superoxide- and Hsp90-dependent events. J Biol Chem 2003;278:35231-40.
24. Burkitt K, Ljungman M. Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin. Mol Cancer 2008;7:24.
25. Mandic R, Schamberger CJ, Müller JF, Geyer M, Zhu L, Carey TE, Grénman R, Dünne AA, Werner JA. Reduced cisplatin sensitivity of head and neck squamous cell carcinoma cell lines correlates with mutations affecting the COOH-terminal nuclear localization signal of p53. Clin Cancer Res 2005;11:6845-52.
26. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using realtime quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25: 402-8.
27. Blagosklonny MV. Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs. Leukemia 2002;16:455-62.
28. Mimnaugh EG, Chavany C, Neckers L. Polyubiquitination and proteasomal degradation of the p185(c-erbB-2) receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 1996;271: 22796-801.
29. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761-72.
30. Arora S, Matta A, Shukla NK, Deo SV, Ralhan R. Identification of differentially expressed genes in oral squamous cell carcinoma. Mol Carcinog 2005;42: 97-108.
31. Husain A, He G, Venkatraman ES, Spriggs DR. BRCA1 up-regulation is associated with repair-mediated resistance to cisdiamminedichloroplatinum (II). Cancer Res 1998;58:1120-3.
32. Cheng TC, Manorek G, Samimi G, Lin X, Berry CC, Howell SB. Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol 2006;58:384-95.
33. Takashima N, Ishiguro H, Kuwabara Y, Kimura M, Mitui A, Mori Y, Mori R, Tomoda K, Hamaguchi M, Ogawa R, Katada T, Harada K, et al.Gene expression profiling of the response of esophageal carcinoma cells to cisplatin. Dis Esophagus 2008;21:230-5.
34. Newell AE, Fiedler SE, Ruan JM, Pan J, Wang PJ, Deininger J, Corless CL, Carr DW. Protein kinase A RII-like (R2D2) proteins exhibit differential localization and AKAP interaction. Cell Motil Cytoskeleton 2008;65:539-52.
35. Lea IA, Richardson RT, Widgren EE, O'Rand MG. Cloning and sequencing of cDNA encoding the human sperm protein, SP17. Biochem Biophys Acta 1996;1307:263-6.
36. Lacy HM, Sanderson RD. Sperm protein 17 is expressed on normal and malignant lymphocytes and promotes heparan sulfate-mediated cell-cell adhesion. Blood 2001;98:2160-5.
37. Lea IA, Widgren EE, O'Rand MG. Association of sperm protein 17 with Akinase anchoring protein 3 in flagella. Reprod Biol Endocrinol 2004;2;57.
38. Li Z, Li W, Meklat F, Wang Z, Zhang J, Zhang Y, Lim SH. A yeast two-hybrid system using Sp17 identified Ropporin as a novel cancer-testis antigen in hematologic malignancies. Int J Cancer 2007;121: 1507-11.
39. Carr DW, Fujita A, Stentz CL, Liberty GA, Olson GE, Narumiya S. Identification of sperm-specific proteins that interact with A-kinase anchoring proteins in a manner similar to the Type II regulatory subunit of PKA. J Biol Chem 2001;276: 17332-8.
40. Fujita A, Nakamura K, Kato T, Watanabe N, Ishizaki T, Kimura K, Mizoguchi A, Narumiya S. Ropporin, a sperm-specific binding protein of rhophilin, that is localized in the fibrous sheath of sperm flagella. J Cell Sci 2000;113: 103-12.